DJIA 17,826.30 -279.47 -1.54%
NASDAQ 4,931.82 -75.98 -1.52%
S&P 500 2,081.18 -23.81 -1.13%
market minute promo

Novartis (NYSE: NVS)

102.46 -0.85 (-0.82%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

NVS $102.46 -0.82%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $102.61
Previous Close $103.31
Daily Range $101.87 - $102.81
52-Week Range $83.71 - $103.80
Market Cap $245.8B
P/E Ratio 27.92
Dividend (Yield) $2.67 (2.2%)
Ex-Dividend Date
Dividend Pay Date
Volume 1,244,351
Average Daily Volume 1,474,825
Current FY EPS $5.27




Drug Makers

Novartis (NVS) Description

Operates in the business of patent-protected and generic pharmaceuticals as well as consumer health products. Website:

News & Commentary

Meet the Game-Changing Drug Designed to Fight America's Leading Cause of Death

This disease claimed more than 600,000 lives in the U.S. in 2013, according to the CDC, but an experimental drug with a possible approval date in 2015 could put a dent in these mortality figures going forward.

Amgen's First Drug For Cardiovascular Disease Gets The Green Light

Novartis and Momenta Get FDA Nod For Generic Copaxone - Analyst Blog

Mylan Scores Final Win In Patent Challenge On Inhalation Drug

Momenta Pharmaceuticals Inc. (MNTA) in Focus: Stock Jumps 6.1% - Tale of the Tape

Pfizer's Ibrance Study Stopped Early on Favorable Data - Analyst Blog

Why Momenta Pharmaceuticals Inc. Shares Are Surging Higher

The FDA has approved Novartis and Momenta Pharmaceuticals, Inc.'s biosimilar to Teva Pharmaceuticals Copaxone.

VEU, NSRGY, NVS, TM: Large Inflows Detected at ETF

3 Potential Blockbuster Drugs That Could Be Approved Before Year's End

Our experts weigh in on some drug candidates with huge potential.

IPO Preview: Aduro Biotech

See More NVS News...

NVS's Top Competitors

NVS $102.46 (-0.82%)
Current stock: NVS
JNJ $99.58 (-0.21%)
Current stock: JNJ
MRK $56.88 (-1.66%)
Current stock: MRK
GSK $47.29 (-0.61%)
Current stock: GSK